Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Terminated 7Completed 6Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 13Genitourinary 6Breast 6Tumor-Agnostic 5Other solid neoplasm 4Thoracic 3Gastrointestinal 3

Conditions

Prostatic Neoplasms 3Ovarian Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Prostate Cancer Metastatic 1Genital Neoplasms, Male 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 116Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Radiosurgery 43Cyclophosphamide 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × rucaparib × Genitourinary × Clear all
NCT03338790 2026-01-27

CheckMate 9KD

Bristol-Myers Squibb

Phase 2 Completed
292 enrolled 21 charts
Genitourinary

Prostatic Neoplasms

NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03413995 2024-10-16

TRIUMPH

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
12 enrolled 11 charts
Genitourinary

Prostate Cancer Metastatic

NCT04676334 2024-05-07

CATCH-R

pharmaand GmbH

Phase 3 Completed
34 enrolled 9 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Hoffmann-La Roche

Phase 1 Completed
51 enrolled 20 charts
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

pharmaand GmbH

Phase 1 Completed
8 enrolled 8 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡